CalciMedica Inc. (NASDAQ:CALC) Short Interest Down 35.7% in August

CalciMedica Inc. (NASDAQ:CALC) saw a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 323,241 shares, a decrease of 35.7% from the July 30th total of 503,070 shares. Based on an average daily volume of 320,704 shares, the short-interest ratio is presently 1.0 days. Currently, 1.3% of the company’s shares are sold short.

Insider Transactions at CalciMedica

In other CalciMedica news, Director Fred A. Middleton bought 49,794 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The shares were bought at an average price of $4.00 per share, with a total value of $199,176.00. Following the purchase, the director owned 212,654 shares of the company’s stock, valued at $850,616. This trade represents a 30.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Several large investors have recently modified their holdings of the business. Envestnet Asset Management Inc. boosted its holdings in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the last quarter. Cetera Investment Advisers increased its position in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after purchasing an additional 18,300 shares during the period. Jane Street Group LLC bought a new position in shares of CalciMedica in the fourth quarter valued at $127,000. Finally, Boothbay Fund Management LLC bought a new position in CalciMedica in the 4th quarter valued at about $506,000.

CalciMedica Stock Down 6.5%

CalciMedica stock traded down $0.14 during midday trading on Tuesday, reaching $2.00. The stock had a trading volume of 139,671 shares, compared to its average volume of 204,280. The firm’s fifty day simple moving average is $3.71 and its 200-day simple moving average is $3.50. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. CalciMedica has a 1-year low of $2.00 and a 1-year high of $36.00. The stock has a market capitalization of $68.28 million, a P/E ratio of -1.47 and a beta of 0.91.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Tuesday, August 11th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.42) by ($0.83). As a group, analysts expect that CalciMedica will post -1.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CALC has been the subject of a number of recent research reports. Guggenheim began coverage on shares of CalciMedica in a research note on Thursday, August 20th. They set a “buy” rating for the company. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Wall Street Zen upgraded CalciMedica to a “sell” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CalciMedica presently has a consensus rating of “Hold” and an average target price of $50.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.